spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  TYSABRI 

 HSMN NewsFeed - 22 Jul 2019
Geron Enhances Oncology Expertise to Advance Corporate Objectives
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 1 Apr 2019
Audentes Therapeutics Appoints Legal and Corporate Communications Executives; Promotes Thomas P. Soloway to Executive Vice President and Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Mar 2017
Perrigo Announces First-To-Market Launch Of The OTC Store Brand Equivalent To Women's Rogaine(R) Foam
Biopharmaceuticals Generics Product Launch
 HSMN NewsFeed - 1 Mar 2017
Perrigo Announces FDA Final Approval For The Generic Version Of Axiron(R) Topical Solution, 30 mg/1.5 mL
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 17 Feb 2017
Perrigo Announces FDA Final Approval For Hydrocodone Bitartrate And Homatropine Methylbromide Oral Solution
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 24 Jan 2017
Perrigo Announces FDA Approval Of Its First-To-File AB Rated Generic Version Of Topicort(R) Spray, 0.25%
Biopharmaceuticals Generics Dermatology FDA
 HSMN NewsFeed - 23 Aug 2016
Perrigo Announces Tentative FDA Approval For Generic Version Of Suprep(R) Oral Solution And Confirms Patent Challenge For Generic Version Of Mirvaso(R) Gel
Biopharmaceuticals Generics FDA Litigation
 HSMN NewsFeed - 21 Jun 2016
Perrigo Announces FDA Clearance And Launch Of Non-GMO* Infant Formulas For The U.S. Store Brand Market
Biopharmaceuticals FDA Product Launch
 HSMN NewsFeed - 2 May 2016
Perrigo Announces FDA Approval and Launch of the Generic Version of BenzaClin(R) Pump Topical Gel
Biopharmaceuticals Generics FDA Product Launch
 HSMN NewsFeed - 23 Mar 2016
Perrigo And Allergan Announce First-To-Market Launch Of Store Brand OTC Equivalent To Mucinex(R) 1200mg ER Tablets
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 10 Nov 2015
Perrigo Announces FDA Approval Of The AB Rated Generic Version Of KlorCon(R) Extended-Release Tablets
Biopharmaceuticals Generics FDA Product Launch
 HSMN NewsFeed - 28 Aug 2015
Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 27 Apr 2015
Amicus Therapeutics Appoints David Allsop as Senior Vice President, International
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Sep 2014
Lumara Health(TM) to be Acquired in Two Separate Transactions for up to $1.107 Billion
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 30 Jan 2014
Biogen Idec and UCB Enter Agreements to Commercialize Multiple Sclerosis and Hemophilia Therapies in Asia
Biopharmaceuticals Licensing
 HSMN NewsFeed - 29 Jan 2014
XenoPort Appoints Richard Kim, M.D., as Chief Medical Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 29 Jul 2013
Perrigo Company to Acquire Elan Corporation, plc for US$8.6 Billion, Establishing Premier Global Healthcare Company
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 20 May 2013
Elan Announces Transactions: Decisively Transforming the Company
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 15 Apr 2013
Royalty Pharma Announces Firm Offer to Acquire Elan
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 6 Feb 2013
Biogen Idec to Acquire Full Rights and Control of TYSABRI(R) from Elan for Upfront Cash and Contingent Payments
Biopharmaceuticals Neurology Acquisitions
 HSMN NewsFeed - 16 Jan 2013
Biogen Idec and Elan Submit Applications for First-Line Use of TYSABRI in Anti-JCV Antibody Negative Patients with MS
Biopharmaceuticals Neurology
 HSMN NewsFeed - 20 Aug 2012
Dyax Corp. Creates COO Position and Expands Executive Roles
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Mar 2012
VIVUS Announced Expansion of Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Mar 2012
Seattle Genetics Appoints Dr. Nancy Simonian to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 20 Jan 2012
Quest Diagnostics STRATIFY JCV(TM) First FDA Market Authorized Antibody-based Blood Test to Help Stratify PML Risk in Multiple Sclerosis Patients
Diagnostics Neurology Personalized Medicine FDA
 HSMN NewsFeed - 29 Sep 2011
Biogen Idec Promotes Tony Kingsley to Run Global Commercial Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Sep 2011
Elan Announces Board of Director Changes
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 11 Apr 2011
Avanir Pharmaceuticals Announces Appointment of William Sibold as Chief Commercial Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 13 Jan 2011
Anders Lundström to Be the New CEO of Orexo
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Jan 2011
Biogen Idec Appoints Doug Williams to Head R&D, Steven Holtzman to Head Corporate Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Dec 2010
Elan Names Robert A. Ingram Chairman-Designate
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Sep 2010
Biogen Idec Makes Statement About U.S. FDA Approval of Gilenya
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 7 Jan 2010
Lycera Appoints Senior Life Sciences Executive William J. Sibold as President and CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Dec 2009
Seasoned Clinical Development Expert Joins Opexa to Lead Tovaxin(R) Development in Multiple Sclerosis
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 14 Sep 2009
Elan Cures Breach of Tysabri(R) Collaboration Agreement and Amends Terms of Transaction with Johnson & Johnson
Biopharmaceuticals Litigation
 HSMN NewsFeed - 15 May 2009
Avila Therapeutics Appoints Katrine S. Bosley as Company's First CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Feb 2009
Elan Announces Further Alignment of Resources as Part of On-Going Strategic Review Process
Biopharmaceuticals
 HSMN NewsFeed - 9 Feb 2009
MS Patients Treated with TYSABRI Remain Free of Disease Activity for Two Years, According to Data Published in the Lancet Neurology
Biopharmaceuticals Neurology
 HSMN NewsFeed - 18 Sep 2008
New Long-Term Data Show That Patients Taking AVONEX(R) for up to 15 Years Experience Reduced Disability Progression and Improved Quality of Life
Biopharmaceuticals Neurology
 HSMN NewsFeed - 5 Sep 2008
Elan and Biogen Idec Initiate First Clinical Trial of TYSABRI(R) in Oncology
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Aug 2008
Monoclonal Antibody Sales to Almost Double in Coming Years
Biopharmaceuticals
 HSMN NewsFeed - 22 Jul 2008
Biogen Idec and Elan Celebrate Second Anniversary of TYSABRI(R) for the Treatment of Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 29 May 2008
Biogen Idec Names Hans Peter Hasler Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 May 2008
Biogen Idec Celebrates 30 Years of Transforming Discovery into Care
Biopharmaceuticals
 HSMN NewsFeed - 15 Apr 2008
Biogen Idec and Elan Present New TYSABRI(R) Data at the 60th Annual Meeting of the American Academy of Neurology
Biopharmaceuticals Neurology
 HSMN NewsFeed - 28 Jan 2008
MicroIslet Announces the Appointments of Dr. Chris Marsh as Lead Transplant Advisor, and Dr. Ronald Goldblum as Lead Clinical Development Consultant
Regenerative Medicine Personnel
 HSMN NewsFeed - 14 Jan 2008
FDA Approves TYSABRI(R) for the Treatment of Moderate-to-Severe Crohn's Disease
Biopharmaceuticals FDA Gastroenterology
 HSMN NewsFeed - 7 Jan 2008
Biogen Idec and Elan Provide Update on Utilization, Safety and Total Patient Exposure of TYSABRI(R) in Patients with Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 1 Nov 2007
Dawn McGuire, M.D. Joins Acologix, Inc. as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Oct 2007
New Long-Term Analysis of Clinical Treatment Outcomes Demonstrated COPAXONE(R) is More Cost Effective Than Tysabri(R) for Treatment of Relapsing-Remitting Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 15 Oct 2007
Elan and Biogen Idec Announce That FDA Will Extend Regulatory Review Period for TYSABRI(R) for Crohn's Disease
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 15 Oct 2007
Elan Update
Biopharmaceuticals
 HSMN NewsFeed - 11 Oct 2007
Biogen Idec and Elan Provide Update on Utilization and Safety of TYSABRI(R) in Patients with Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 20 Aug 2007
TYSABRI(R) Demonstrates Significant Health-Related Quality-of-Life Improvements for Multiple Sclerosis Patients in Study Published in Annals of Neurology
Biopharmaceuticals Neurology
 HSMN NewsFeed - 31 Jul 2007
Joint FDA Advisory Committee Recommends Approval of TYSABRI(R) for the Treatment of Moderate to Severe Crohn's Disease
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 31 Jul 2007
OXiGENE Appoints Patricia Walicke, M.D., Ph.D. as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 31 Jul 2007
Accentia Biopharmaceuticals Files Pre-Investigational New Drug (IND) Application with FDA for Pivotal Phase 3 Clinical Trial of Revimmune for Refractory Multiple Sclerosis
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 23 Jul 2007
TYSABRI(R) Celebrates One-Year Anniversary as a Treatment for Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 20 Jul 2007
Biotechnology Start-up Nuon Therapeutics Inc. Completes $5 Million Series A Financing and Names Management Team
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 19 Jul 2007
Elan and Biogen Idec Preparing to Appeal Ruling on European Application for Natalizumab for the Treatment of Crohn's Disease
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 18 Jun 2007
Oculus Innovative Sciences Appoints Vice President of Regulatory Affairs and Quality
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 May 2007
Elan and Biogen Idec Announce a FDA Advisory Committee Meeting to Review TYSABRI(R) for the Treatment of Crohn's Disease
Biopharmacetuicals Gastroenterology FDA
 HSMN NewsFeed - 3 May 2007
Data Presented at the American Academy of Neurology's Annual Meeting Provide Update on Utilization and Safety of TYSABRI(R) in Patients with Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 30 Jan 2007
Teva Receives Approval for Generic Focalin(TM) Tablets
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 24 Jan 2007
Teva Files Patent Infringement Complaints Regarding Sertraline Hydrochloride
Biopharmaceuticals Litigation
 HSMN NewsFeed - 22 Dec 2006
Largest Disease Modification Trial for Parkinson's Disease Completes Enrollment
Biopharmaceuticals Neurology
 HSMN NewsFeed - 15 Dec 2006
Elan and Biogen Idec Submit Supplemental Biologics License Application to the FDA for the Approval of TYSABRI(R) as a Treatment for Crohn's Disease
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 29 Nov 2006
Teva Announces Tentative Approval of Sumatriptan Succinate Tablets
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 21 Nov 2006
Teva Announces Agreement with Pfizer Regarding Idarubicin, Azithromycin, and Epirubicin
Biopharmaceuticals Litigation
 HSMN NewsFeed - 14 Nov 2006
Court of Appeals Affirms Teva's Generic Zocor(R) Exclusivity
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 24 Oct 2006
TYSABRI(R) Maintained Remission in Patients with Moderate-to-Severe Crohn's Disease Treated for Longer Than Two Years According to Data Presented This Week
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 18 Oct 2006
TEVA Announces Planned Retirement of President & CEO in 2007
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Oct 2006
Teva Announces OxyContin(R) Litigation Dismissed; Settlement with Purdue Finalized
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 12 Oct 2006
Teva Announces Tentative Approval for Generic Risperdal(R) Oral Solution
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 6 Oct 2006
New Pharmacoeconomic Data on TYSABRI(R) Demonstrate Significant Reduction in Steroid Use and Hospitalizations in Patients with Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 3 Oct 2006
Long-Term Data Demonstrated Significantly Better Patient Adherence to COPAXONE(R) versus Interferons in Multiple Sclerosis Treatment
Biopharmaceuticals Neurology
 HSMN NewsFeed - 2 Oct 2006
COPAXONE(R) Showed Sustained Benefit on Slowing Brain Tissue Damage in Multiple Sclerosis Patients
Biopharmaceuticals Neurology
 HSMN NewsFeed - 29 Sep 2006
New Data Presented at ECTRIMS Congress Show TYSABRI(R) Has Sustained Effect on Relapse Rate in Multiple Sclerosis Patients Treated for up to Three Years
Biopharmaceuticals Neurology
 HSMN NewsFeed - 29 Sep 2006
Very Active Multiple Sclerosis Patients Benefited from COPAXONE(R) Treatment Following Short-Term Induction with Mitoxantrone
Biopharmaceuticals Neurology
 HSMN NewsFeed - 29 Sep 2006
Study Showed Significant and Sustained Efficacy Of COPAXONE(R) Alone Following Short-Term Combination Therapy With IV Steroids in Multiple Sclerosis Patients
Biopharmaceuticals Neurology
 HSMN NewsFeed - 28 Sep 2006
New Data Confirmed Antibodies to COPAXONE(R) do not Impact Its Established and Sustained Long-Term Efficacy in Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 28 Sep 2006
New Data on TYSABRI(R) Presented at ECTRIMS Congress Demonstrate Significant Improvement in Cognitive Function in Patients with Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 26 Sep 2006
Teva Pharmaceutical Industries Ltd. and Protalix Biotherapeutics Ltd. Announce a Collaboration Agreement for the Development of Two Biopharmaceuticals, Based on Protalix's Recombinant Plant Cell Expression Technology
Biopharmaceuticals Licensing
 HSMN NewsFeed - 29 Aug 2006
Teva Announces Settlement of OxyContin(R) Litigation
Biopharmaceuticals Litigation
 HSMN NewsFeed - 21 Aug 2006
Teva Announces Health Canada Approves AZILECT(R) (Rasagiline) for Parkinson's Disease
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 21 Aug 2006
First Patient Enrolled in Study to Evaluate Impact of Regular Neutralizing Antibody (NAb) Testing on Multiple Sclerosis Treatment Patterns
Biopharmaceuticals Neurology
 HSMN NewsFeed - 14 Aug 2006
Teva Announces Launch of Generic Zoloft(R)
Biopharmaceuticals Generics
 HSMN NewsFeed - 4 Aug 2006
Teva Announces Final Approval of Venlafaxine HCl Tablets
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 31 Jul 2006
Teva Neuroscience Announces AZILECT(R) Is Now Available in Pharmacies - the First, Once-Daily Treatment for Parkinson's Disease
Biopharmaceuticals Neurology
 HSMN NewsFeed - 27 Jul 2006
Teva Initiates Phase III Study to Confirm Increased Efficacy of Higher Dose of Glatiramer Acetate for the Treatment of Relapsing-Remitting Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 24 Jul 2006
Biogen Idec and Elan Announce Availability of TYSABRI(R) for the Treatment of Relapsing Forms of Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 20 Jul 2006
Teva Announces Final Approval of Meloxicam Tablets
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 12 Jul 2006
Teva Announces Tentative Approval of Generic Lotrel(R) Capsules
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 12 Jul 2006
Teva Will Be Sole Promoter of AZILECT(R) for Parkinson's Disease in the United States
Biopharmaceuticals Neurology
 HSMN NewsFeed - 30 Jun 2006
Teva Receives FDA Approval for Generic Zoloft(R) Tablets
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 30 Jun 2006
OXiGENE'S Board of Directors Names Experienced Biotech Executive, Richard Chin, M.D., as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Jun 2006
TYSABRI(R) Receives Approval in European Union for the Treatment of Relapsing Remitting Forms of Multiple Sclerosis
Biopharmaceuticals Regulatory Neurology
 HSMN NewsFeed - 27 Jun 2006
Teva Provides Generic Biaxin(R) XL Update
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 23 Jun 2006
Teva Receives First U.S. Approval of Generic Zocor(R) Tablets
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 23 Jun 2006
Teva Announces Novartis' Sandoz Unit Seeks to Delay First FDA Approval of Generic Zocor(R)
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 22 Jun 2006
Court of Appeals Rules in Favor of Teva on Biaxin(R) XL Preliminary Injunction
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 21 Jun 2006
Mark Matthews Joins Javelin Pharmaceuticals as VP of Commercial Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Jun 2006
COPAXONE(R) Reduced Relapses By 75 Percent in Both Treatment-Naive Multiple Sclerosis Patients and Those Failing Betaseron(R)
Biopharmaceuticals Neurology
 HSMN NewsFeed - 19 Jun 2006
Teva Receives First FDA Approval for Generic Proscar(R) Tablets
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 14 Jun 2006
Teva Announces Tentative Approval of Losartan Potassium & Hydrochlorothiazide Tablets
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 5 Jun 2006
FDA Approves the Reintroduction of TYSABRI(R) for the Treatment of Relapsing Forms of Multiple Sclerosis
Biopharmaceuticals FDA Neurology
 HSMN NewsFeed - 28 May 2006
Teva Announces Tentative Approval for Generic Cozaar(R) Tablets
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 25 May 2006
Teva Announces Tentative Approval of Simvastatin Tablets
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 22 May 2006
Teva Announces Approval of Generic Lexapro(R) Tablets
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 17 May 2006
AZILECT(R) FDA Approval Brings New Hope to People Living With Parkinson's Disease
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 17 May 2006
Teva Announces FDA Grants Approval of AZILECT(R) (Rasagiline) for Parkinson's Disease
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 7 May 2006
Teva Announces Approval of Polyethylene Glycol 3350 NF for Oral Solution
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 1 May 2006
District Court Grants Teva Summary Judgment for Generic Zocor(R) Exclusivity
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 28 Apr 2006
CHMP Issues Positive Opinion for TYSABRI(R) as a Treatment for Relapsing-Remitting Multiple Sclerosis
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 25 Apr 2006
Teva Receives First FDA Approval for Generic Pravachol(R)
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 21 Apr 2006
Teva Provides Update on Generic Pravachol(R)
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 20 Apr 2006
Teva Announces Stay of Approval for Generic Pravachol Lifted
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 19 Apr 2006
District Court Denies Apotex's Request to Block Teva's Introduction of First Generic Pravachol(R) In The U.S.
Biopharmaceuticals Generics FDA Litigation
 HSMN NewsFeed - 13 Apr 2006
ArQule Announces Management and Board Changes
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Apr 2006
New Data on TYSABRI(R) Demonstrate Significant Effects on Health-Related Quality of Life Measures in Patients with Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 29 Mar 2006
Biogen Idec and Elan Announce Re-Initiation of TYSABRI(R) Clinical Trial Dosing in Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 22 Mar 2006
Biogen Idec and Elan Announce That FDA Will Extend Regulatory Review Period for the Reintroduction of TYSABRI(R) for Multiple Sclerosis
Biopharmaceuticals FDA Neurology
 HSMN NewsFeed - 8 Mar 2006
FDA Advisory Committee Unanimously Recommends Reintroduction of TYSABRI(R) for the Treatment of Relapsing Forms of Multiple Sclerosis
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 1 Mar 2006
TYSABRI(R) Two-Year Phase III Multiple Sclerosis Clinical Trial Results and Safety Evaluation Published in New England Journal of Medicine
Biopharmaceuticals Neurology
 HSMN NewsFeed - 23 Jan 2006
Biogen Idec and Elan Announce Notification of FDA Advisory Committee Meeting to Review TYSABRI(R) for the Treatment of Multiple Sclerosis
Biopharmaceuticals FDA Neurology
Return to NewsFeed  

 Additional items found! 29

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 29 additional stories matching:
TYSABRI
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.